UPDATE: Baird Starts Tesaro (TSRO) at Outperform; Proven Management Team and Business Model
Tweet Send to a FriendGet Alerts TSRO Hot Sheet
Price: $35.99 -7.07%
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Trade TSRO Now!
(Updated - July 23, 2012 7:53 AM EDT)
Baird initiates coverage on Tesaro (NASDAQ: TSRO) with an Outperform. PT $19.00.
Analyst, Christopher Raymond, said, "Buyers of TSRO into the high teens as we believe shares can work higher in the intermediate-to-longer term as the clinical profiles of early-stage cancer therapeutics TSR-011 (ALK inhibitor) and niraparib (PARP inhibitor) emerge early next year and as rolapitant (CINV supportive-care agent) Phase III data approaches 2H13. Coupling a well-proven management team and exceptionally strong balance sheet with what we see as lower-than-average execution risk, we think this name is worth a look for any growth-oriented small-cap investor."
For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.
Shares of Tesaro closed at $13.50 yesterday, with a 52 week range of $12.82-$14.18.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Baird initiates coverage on Tesaro (NASDAQ: TSRO) with an Outperform. PT $19.00.
Analyst, Christopher Raymond, said, "Buyers of TSRO into the high teens as we believe shares can work higher in the intermediate-to-longer term as the clinical profiles of early-stage cancer therapeutics TSR-011 (ALK inhibitor) and niraparib (PARP inhibitor) emerge early next year and as rolapitant (CINV supportive-care agent) Phase III data approaches 2H13. Coupling a well-proven management team and exceptionally strong balance sheet with what we see as lower-than-average execution risk, we think this name is worth a look for any growth-oriented small-cap investor."
For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.
Shares of Tesaro closed at $13.50 yesterday, with a 52 week range of $12.82-$14.18.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Canaccord Genuity Starts T-Mobile US, (TMUS) at Hold
- WallachBeth Capital Starts Momenta Pharmaceuticals (MNTA) at Buy
- Deutsche Bank Starts Quintiles (Q) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Robert W Baird
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
